No. |
Chromosome Location |
Chromatin state |
Cell line |
Tissue |
1 |
chr21:37912400-37916400 |
Weak transcription |
Pancreas |
Pancrea
|
2 |
chr21:37914200-37915200 |
Enhancers |
iPS DF 19.11 Cell Line |
embryonic stem cell
|
3 |
chr21:37914400-37915600 |
Bivalent Enhancer |
hESC Derived CD56+ Ectoderm Cultured Cells |
ES cell derived
|
4 |
chr21:37914600-37915000 |
Flanking Bivalent TSS/Enh |
ES-I3 Cell Line |
embryonic stem cell
|
5 |
chr21:37914600-37915000 |
Bivalent Enhancer |
HUES48 Cell Line |
embryonic stem cell
|
6 |
chr21:37914600-37915000 |
Flanking Bivalent TSS/Enh |
HUES64 Cell Line |
embryonic stem cell
|
7 |
chr21:37914600-37915200 |
Bivalent/Poised TSS |
ES-WA7 Cell Line |
embryonic stem cell
|
8 |
chr21:37914600-37915200 |
Bivalent Enhancer |
H9 Derived Neuron Cultured Cells |
ES cell derived
|
9 |
chr21:37914600-37915200 |
Bivalent Enhancer |
hESC Derived CD184+ Endoderm Cultured Cells |
ES cell derived
|
10 |
chr21:37914600-37915200 |
Flanking Bivalent TSS/Enh |
HUES6 Cell Line |
embryonic stem cell
|
11 |
chr21:37914600-37915200 |
Bivalent/Poised TSS |
iPS-20b Cell Line |
embryonic stem cell
|
12 |
chr21:37914600-37915200 |
Bivalent Enhancer |
Primary hematopoietic stem cells G-CSF-mobilized Female |
--
|
13 |
chr21:37914600-37915200 |
Bivalent Enhancer |
Foreskin Melanocyte Primary Cells skin01 |
Skin
|
14 |
chr21:37914600-37915200 |
Bivalent Enhancer |
Foreskin Melanocyte Primary Cells skin03 |
Skin
|
15 |
chr21:37914600-37915600 |
Enhancers |
ES-UCSF4 Cell Line |
embryonic stem cell
|
16 |
chr21:37914600-37915600 |
Flanking Active TSS |
GM12878-XiMat |
blood
|
17 |
chr21:37914800-37915000 |
Flanking Active TSS |
H1 Cell Line |
embryonic stem cell
|
18 |
chr21:37914800-37915000 |
Bivalent Enhancer |
iPS-18 Cell Line |
embryonic stem cell
|
19 |
chr21:37914800-37915000 |
Bivalent Enhancer |
Primary T cells fromperipheralblood |
blood
|
20 |
chr21:37914800-37915000 |
Bivalent Enhancer |
Primary hematopoietic stem cells G-CSF-mobilized Male |
--
|
21 |
chr21:37914800-37915000 |
Bivalent Enhancer |
Esophagus |
oesophagus
|
22 |
chr21:37914800-37915000 |
Bivalent Enhancer |
Fetal Lung |
lung
|
23 |
chr21:37914800-37915000 |
Flanking Bivalent TSS/Enh |
Fetal Muscle Trunk |
muscle
|
24 |
chr21:37914800-37915000 |
Flanking Bivalent TSS/Enh |
Fetal Muscle Leg |
muscle
|
25 |
chr21:37914800-37915000 |
Bivalent Enhancer |
Fetal Thymus |
thymus
|
26 |
chr21:37914800-37915000 |
Bivalent Enhancer |
Thymus |
Thymus
|
27 |
chr21:37914800-37915200 |
Active TSS |
iPS-15b Cell Line |
embryonic stem cell
|
28 |
chr21:37914800-37915200 |
Bivalent Enhancer |
Primary B cells from peripheral blood |
blood
|
29 |
chr21:37914800-37915200 |
Enhancers |
Primary hematopoietic stem cells |
blood
|
30 |
chr21:37914800-37915200 |
Bivalent Enhancer |
Primary Natural Killer cells fromperipheralblood |
blood
|
31 |
chr21:37914800-37915200 |
Flanking Bivalent TSS/Enh |
Placenta |
Placenta
|
32 |
chr21:37914800-37915200 |
Bivalent Enhancer |
Placenta Amnion |
Placenta Amnion
|
33 |
chr21:37914800-37915400 |
Enhancers |
iPS DF 6.9 Cell Line |
embryonic stem cell
|
34 |
chr21:37914800-37915400 |
Bivalent Enhancer |
Fetal Adrenal Gland |
Adrenal Gland
|